Review
Version 1
Preserved in Portico This version is not peer-reviewed
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
Version 1
: Received: 25 July 2023 / Approved: 25 July 2023 / Online: 26 July 2023 (10:07:16 CEST)
A peer-reviewed article of this Preprint also exists.
Bang, J.; Jun, M.; Lee, S.; Moon, H.; Ro, S.W. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma. Pharmaceutics 2023, 15, 2130. Bang, J.; Jun, M.; Lee, S.; Moon, H.; Ro, S.W. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma. Pharmaceutics 2023, 15, 2130.
Abstract
Hepatocellular carcinoma (HCC) poses a significant global health concern, with its incidence steadily increasing. The development of HCC is a multifaceted, multi-step process involving alterations in various signaling cascades. In recent years, significant progress has been made in understanding the molecular signaling pathways that play central roles in hepatocarcinogenesis. In particular, the EGFR/PI3K/Akt/mTOR signaling pathway in HCC has garnered renewed attention from both basic and clinical researchers. Preclinical studies in vitro and in vivo have shown the effectiveness of targeting the key components of this signaling pathway in human HCC cells. Thus, targeting these signaling pathways with small molecule inhibitors holds promise as a potential therapeutic option for patients with HCC. In this review, we will explore recent advancements in understanding the role of the EGFR/PI3K/Akt/mTOR signaling pathway in HCC and assess the effectiveness of targeting this signaling cascade as a potential strategy for HCC therapy based on preclinical studies
Keywords
hepatocellular carcinoma; EGFR/PI3K/AKT/mTOR signaling; animal models; Targeted Therapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment